Evaluation of the bioequivalence of single 100-mg doses of two oral formulations of cyclosporin a microemulsion: A randomized, open-label, two-period crossover study in healthy adult male mexican volunteers

Clinical Therapeutics

Volumn 29, Issue 9, 2007, Pages 2049-2054

  Piñeyro López, Alfredo ^a   Piñeyro Garza, Everardo ^a   Torres Alanís, Oscar ^a   Reyes Araiza, Ratúl ^a   Gómez Silva, Magdalena ^a   Waksman, Noemí ^a   E Salazar Leal, Martha ^a   Luján Rangel, Rubén ^a  

^a Centro Regional de Alergia   (Mexico)

Author keywords

bioavailability; bioequivalence; cyclosporin A; human; mass spectrometry; pharmacokinetics

Indexed keywords

CYCLOSPORIN A; UNCLASSIFIED DRUG; ZAVEN ME;

ABSENCE OF SIDE EFFECTS; ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG ABSORPTION; DRUG FORMULATION; HUMAN; HUMAN EXPERIMENT; MALE; MASS SPECTROMETRY; MAXIMUM PLASMA CONCENTRATION; MEXICO; MICROEMULSION; NORMAL HUMAN; OPEN STUDY; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE;

ADMINISTRATION, ORAL; ADULT; ANALYSIS OF VARIANCE; AREA UNDER CURVE; CAPSULES; CHEMISTRY, PHARMACEUTICAL; CROSS-OVER STUDIES; CYCLOSPORINE; EMULSIONS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MEXICO; THERAPEUTIC EQUIVALENCY;

EID: 36749019115     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2007.09.004     Document Type: Article

References (13)

1. Cyclosporine A., Reents S., and Seymour J. Clinical Pharmacology2000 \CD-ROM]. Tampa, Fla: Gold Standard Multimedia, Inc; (2001)
2. Krensky A.M., Strom T.B., and Bluestone J.A. Immunomodulators: Immunosuppressive agents, tolerogens, and immunostimulants. In: Hardman J.G., and Limbird L.E. (Eds). Goodman & Gilman's The Pharmacological Basis of Therapeutics. 10th (2001), McGraw-Hill Medical Publishing Division, New York, NY 1463-1484
3. Reynolds J.E. Cyclosporine. The Extra Pharmacopoeia/Martindale. 31st (1996), Pharmaceutical Press, London, UK 557-562
4. World Medical Association Declaration of Helsinki. Ethical principles for medical research involving human subjects. (August 16, 2006). http://www.wma.net/e/policy/b3.htm
5. Volosov A., Napoli K.L., and Soldin S.J. Simultaneous simple and fast quantification of three major immunosuppressants by liquid chromatography-tandem mass-spectrometry. Clin Biochem. 34 (2001) 285-290
6. Center for Drug Evaluation and Research, US Food and Drug Administration. Guidance for industry. Bioanalytical method validation. (August 16, 2006). http://www.fda.gov/cder/guidance/4252fnl.htm
7. Ministry of Health of Mexico. Official Mexican standard NOM-177-SSA1-1998, which establishes proofs and procedures for demonstrating that a medication is interchangeable \in Spanish]. (June 5, 2006) http://www.salud. gob.mx/unidades/cdi/nom/177ssa18.html.
8. US Food and Drug Administration. In vivo bioequivalence guidances. Pharmacopeial Forum. 19 (1993) 6501-6508
9. Schuirmann D.J. A comparison of the two one-sided test procedure and the power approach for assessing the equivalence of average bioavailability. J Pharmacokinet Biopharm. 15 (1987) 657-680
10. Statistical methods for average bioavailability and bioequivalence studies. In: Chow S.C., and Liu J.P. (Eds). Design and Analysis of Bioavailability and Bioequivalence Studies. 2nd (2000), Marcel Dekker, New York, NY 79-124
11. Chow S.C., and Liu J.P. Power and sample size determination. Design and Analysis of Bioavai/ability and Bioequivalence Studies. 2nd (2000), Marcel Dekker, New York, NY: 125-160
12. Najib N.M., Idkaidek N., Adel A., et al. Comparison of two cyclosporine formulations in healthy Middle Eastern volunteers: Bioequivalence of the new Sigmasporin Micro-oral and Sandimmun Neoral. EurJ Pharm Biopharm. 55 (2003) 67-70
13. Mendes G.D., de Oliveira C.H., Sucupira M., et al. Cyclosporine bioequivalence study:Quantification using fluorescence polarization immunoassay (FPlA) and radio immunoassay (RIA). Int J Clin Pharmacol Ther. 42 (2004) 125-132